To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
January 2019

Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls

Vol: 8| Issue: 1| Number:24| ISSN#: 2564-2537
Study Type:Meta-analysis/Systematic Review
OE Level Evidence:1
Journal Level of Evidence:N/A

Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and metaanalysis

Expert Opin Drug Saf. 2018 Apr;17(4):413-428

Contributing Authors:
EI Kenanidis ME Potoupnis E Tsiridis A Fontalis E Prousali

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

6 randomized controlled trials were included in this meta-analysis which aimed to compare increase in bone mineral density measurements between denosumab and other active anti-osteoporosis medications among postmenopausal women with osteoporosis and who had previously been administered anti-osteoporosis therapy. In pooled analyses, percent increase in bone mineral density measured at the total hip...

Join the Conversation

Please Login or Join to leave comments.